William D. Tap, MD

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

William D. Tap, MD, discusses the FDA approval of vimseltinib for patients with symptomatic TGCT and this agent's role in the treatment paradigm.

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

William D. Tap, MD, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

William D. Tap, MD, discusses future research efforts in sarcoma.

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

William D. Tap, MD, discusses the importance of ​community and academic collaboration in sarcoma.

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the idea of using combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.